Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| AUCATZYL/Obecabtagene Autoleucel (AUTO1) (CD19 CAR-T) | Lupus Nephritis | Phase 2 | Dec 31, 2028 | — |
| AUCATZYL/Obecabtagene Autoleucel (AUTO1) (CD19 CAR-T) | Pediatric Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukemia And B-Cell Non-Hodgkin Lymphoma | Phase 2 | Dec 31, 2027 | — |
| obe-cel (AUTO1) (CD19) | Systemic lupus erythematosus | Phase 1 | Dec 31, 2026 | — |
Upcoming milestones
Company profile
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Systemic lupus erythematosus
Data readoutRelapsed Or Refractory Light-Chain (AL) Amyloidosis
Data readout